A group of Spanish researchers have found a new therapeutic route for treatment of inflammatory and metabolic diseases such as obesity or type 2 diabetes (DM2). The work suggests that the metabolic health of people with these pathologies could experience an improvement by reducing the levels of succinate in their blood through the administration of specific bacteria that act as probiotics.
Succinate is a metabolite with multiple functions that produce naturally the cells of the organism and the intestinal bacteria or microbiota. In metabolic and inflammatory diseases with an alteration of the intestinal microbiota, the production levels of this metabolite are eight times higher. In other words, it is directly related to the characteristic inflammation in this type of patient.
In metabolic and inflammatory diseases with an alteration of the intestinal microbiota, the levels of production of the metabolite are eight times higher
Precisely, several previous studies by Diamet, the research group that has led this study and is coordinated by doctors Sonia Fernandez-Veledo Y Joan Vendrell, showed that detecting high blood levels of this metabolite indicates that the person does not enjoy good metabolic health. Therefore, in the future you have increased risk of developing other pathologies. Therefore, it is a key indicator. “In previous research we basically showed that these patients had more succinate-producing bacteria and less succinate-consuming ones. However, we had not been able to prove a direct causal relationship.explains Dr. Fernández-Veledo.
“In this research, using microbiota-free obese animal models, we show for the first time that gut microbiota it is the origin of the increased levels of succinate in obesity and diabetes. This new line of probiotics is based on the use of succinate consuming bacteria. In this way, they would reduce inflammation and, consequently, improve glycemic levels and insulin sensitivity. That is, two aspects that are altered in people with diabetes”, adds the specialist.
Dr. Sonia Fernández-Veledo: “The intestinal microbiota is the origin of the increased levels of succinate in obesity and diabetes”
Investigating in these areas is crucial since, according to data from the World Health Organization (WHO), the incidence of obesity in the world population has tripled the last 50 years. This disease is the most important risk factor for the development of diabetes. The 80% of the people who suffer from it are obese. In turn, it is considered by the WHO the ninth leading cause of death in the world.
In addition, this new line of probiotics allow monitor its effectiveness in real time as «thanks to this study, we now know its mechanism of action«highlights isabel huber, first signing author of the scientific article. On the other hand, she assures that the result of the activity of these bacteria is easily measurable in blood. “Although it is known that many of the probiotics that are used on the market today are beneficial, many times how they really work is unknown and, therefore, their effect cannot be objectively determined”.
The research, carried out by the Institut d’Investigació Sanitària Pere Virgi (Iispv)-Cerca, the Universitat Rovira i Virgili (URV) and the Network Biomedical Research Center for Diabetes and Associated Metabolic Diseases (Ciberdem), has been published in the scientific journal microbiome.